Evidence map›Paper›PMID 33619502›Full record

ArticlemedRxiv : the preprint server for health sciences2021

In depth analysis of patients with severe SARS-CoV-2 in sub-Saharan Africa demonstrates distinct clinical and immunological profiles.

B Morton, K G Barnes, C Anscombe, K Jere, R Kamng'ona, C Brown, J Nyirenda, T Phiri, N Banda, C Van Der Veer and 13 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors at 4 institutions in 3 countries.

B MortonMalawi-Liverpool-Wellcome Trust Clinical Research Programme, University of Malawi College of Medicine, Blantyre, Malawi.
K G BarnesMalawi-Liverpool-Wellcome Trust Clinical Research Programme, University of Malawi College of Medicine, Blantyre, Malawi.
C AnscombeMalawi-Liverpool-Wellcome Trust Clinical Research Programme, University of Malawi College of Medicine, Blantyre, Malawi.
K JereMalawi-Liverpool-Wellcome Trust Clinical Research Programme, University of Malawi College of Medicine, Blantyre, Malawi.
R Kamng'onaMalawi-Liverpool-Wellcome Trust Clinical Research Programme, University of Malawi College of Medicine, Blantyre, Malawi.
C BrownMalawi-Liverpool-Wellcome Trust Clinical Research Programme, University of Malawi College of Medicine, Blantyre, Malawi.
J NyirendaMalawi-Liverpool-Wellcome Trust Clinical Research Programme, University of Malawi College of Medicine, Blantyre, Malawi.
T PhiriDepartment of Medicine, Queen Elizabeth Central Hospital, Blantyre, Malawi.
N BandaUniversity of Malawi-College of Medicine, Blantyre, Malawi.
C Van Der VeerMalawi-Liverpool-Wellcome Trust Clinical Research Programme, University of Malawi College of Medicine, Blantyre, Malawi.
K S MndoloDepartment of Medicine, Queen Elizabeth Central Hospital, Blantyre, Malawi.
K MpondaDepartment of Medicine, Queen Elizabeth Central Hospital, Blantyre, Malawi.
J RylanceMalawi-Liverpool-Wellcome Trust Clinical Research Programme, University of Malawi College of Medicine, Blantyre, Malawi.
C PhiriDepartment of Medicine, Queen Elizabeth Central Hospital, Blantyre, Malawi.
J MallewaUniversity of Malawi-College of Medicine, Blantyre, Malawi.
M NyirendaUniversity of Malawi-College of Medicine, Blantyre, Malawi.
G KathaDepartment of Medicine, Queen Elizabeth Central Hospital, Blantyre, Malawi.
P KambiyaMalawi-Liverpool-Wellcome Trust Clinical Research Programme, University of Malawi College of Medicine, Blantyre, Malawi.
J JafaliMalawi-Liverpool-Wellcome Trust Clinical Research Programme, University of Malawi College of Medicine, Blantyre, Malawi.
H C MwandumbaMalawi-Liverpool-Wellcome Trust Clinical Research Programme, University of Malawi College of Medicine, Blantyre, Malawi.
S B GordonMalawi-Liverpool-Wellcome Trust Clinical Research Programme, University of Malawi College of Medicine, Blantyre, Malawi.
J CornickMalawi-Liverpool-Wellcome Trust Clinical Research Programme, University of Malawi College of Medicine, Blantyre, Malawi.
K C JamboMalawi-Liverpool-Wellcome Trust Clinical Research Programme, University of Malawi College of Medicine, Blantyre, Malawi.
University of Liverpool · GBQueen Elizabeth Central Hospital · MWUniversity of Malawi · MWBroad Institute · US

Funding

Identifying genetic determinants of Rotavirus Vaccine Failure in Malawian ChildrenK01TW010853 · FIC · HARVARD SCHOOL OF PUBLIC HEALTH · PI BARNES, KAYLA G · 2018 to 2022
$731k
FIC NIH HHS K01 TW010853Wellcome Trust 211433/Z/18/Z
6 · The paper itself

Abstract

Although the COVID-19 pandemic has left no country untouched there has been limited research to understand clinical and immunological responses in African populations. Here we comprehensively characterise patients hospitalised with suspected or confirmed COVID-19, and healthy community controls. PCR-confirmed COVID-19 participants were more likely to receive dexamethasone and a beta-lactam antibiotic, and survive to hospital discharge than PCR-/IgG+ and PCR-/IgG-participants. PCR-/IgG+ participants exhibited a nasal and systemic cytokine signature analogous to PCR-confirmed COVID-19 participants, but increased propensity for

Identifiers

PMID33619502
PMCPMC7899472
OpenAlexW3131599831

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.